{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:44:41Z","timestamp":1790768681768,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2015,7,23]],"date-time":"2015-07-23T00:00:00Z","timestamp":1437609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009230","name":"Norris Cotton Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Although genetic profiling of tumors is a potentially powerful tool to predict drug sensitivity and resistance, its routine use has been limited because clinicians are often unfamiliar with interpretation and incorporation of the information into practice. We established a Molecular Tumor Board (MTB) to interpret individual patients\u2019 tumor genetic profiles and provide treatment recommendations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>DNA from tumor specimens was sequenced in a Clinical Laboratory Improvement Amendments-certified laboratory to identify coding mutations in a 50-gene panel (n = 34) or a 255-gene panel (n = 1). Cases were evaluated by a multidisciplinary MTB that included pathologists, oncologists, hematologists, basic scientists, and genetic counselors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>During the first year, 35 cases were evaluated by the MTB, with 32 presented for recommendations on targeted therapies, and 3 referred for potential germline mutations. In 56.3% of cases, MTB recommended treatment with a targeted agent based on evaluation of tumor genetic profile and treatment history. Four patients (12.5%) were subsequently treated with a MTB-recommended targeted therapy; 3 of the 4 patients remain on therapy, 2 of whom experienced clinical benefit lasting &amp;gt;10 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>For the majority of cases evaluated, the MTB was able to provide treatment recommendations based on targetable genetic alterations. The most common reasons that MTB-recommended therapy was not administered stemmed from patient preferences and genetic profiling at either very early or very late stages of disease; lack of drug access was rarely encountered. Increasing awareness of molecular profiling and targeted therapies by both clinicians and patients will improve acceptance and adherence to treatments that could significantly improve outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice:<\/jats:title>\n                  <jats:p>Case evaluation by a multidisciplinary Molecular Tumor Board (MTB) is critical to benefit from individualized genetic data and maximize clinical impact. MTB recommendations shaped treatment options for the majority of cases evaluated. In the few patients treated with MTB-recommended therapy, disease outcomes were positive and support genetically informed treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0097","type":"journal-article","created":{"date-parts":[[2015,7,24]],"date-time":"2015-07-24T02:29:56Z","timestamp":1437704996000},"page":"1011-1018","source":"Crossref","is-referenced-by-count":82,"title":["Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center"],"prefix":"10.1093","volume":"20","author":[{"given":"Laura J.","family":"Tafe","sequence":"first","affiliation":[{"name":"Department of Pathology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan P.","family":"Gorlov","sequence":"additional","affiliation":[{"name":"Department of Community and Family Medicine, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine B.","family":"de Abreu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel A.","family":"Lefferts","sequence":"additional","affiliation":[{"name":"Department of Pathology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Pettus","sequence":"additional","affiliation":[{"name":"Department of Pathology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Marotti","sequence":"additional","affiliation":[{"name":"Department of Pathology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasia J.","family":"Bloch","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Breast Program, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"},{"name":"Department of Familial Cancer Program, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent A.","family":"Memoli","sequence":"additional","affiliation":[{"name":"Department of Pathology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arief A.","family":"Suriawinata","sequence":"additional","affiliation":[{"name":"Department of Pathology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin H.","family":"Dragnev","sequence":"additional","affiliation":[{"name":"Department of Medicine, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo E.","family":"Fadul","sequence":"additional","affiliation":[{"name":"Department of Medicine, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary N.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"},{"name":"Department of Comprehensive Breast Program, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton R.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Breast Program, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt M.","family":"Holderness","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Breast Program, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Pathology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Tsongalis","sequence":"additional","affiliation":[{"name":"Department of Pathology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd W.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Toxicology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"},{"name":"Department of Comprehensive Breast Program, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary D.","family":"Chamberlin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"},{"name":"Department of Comprehensive Breast Program, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,7,23]]},"reference":[{"key":"2021122309372011400_B1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ctrv.2010.07.004","article-title":"Use of molecular markers for predicting therapy response in cancer patients","volume":"37","author":"Duffy","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"2021122309372011400_B2","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122309372011400_B3","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1158\/1078-0432.CCR-14-0603","article-title":"Personalized medicine for patients with advanced cancer in the phase I program at M.D. Anderson: Validation and landmark analyses","volume":"20","author":"Tsimberidou","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021122309372011400_B4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","article-title":"The BATTLE trial: Personalizing therapy for lung cancer","volume":"1","author":"Kim","year":"2011","journal-title":"Cancer Discov"},{"key":"2021122309372011400_B5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1515\/cclm-2013-0883","article-title":"Routine use of the Ion Torrent AmpliSeq\u2122 Cancer Hotspot Panel for identification of clinically actionable somatic mutations","volume":"52","author":"Tsongalis","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"2021122309372011400_B6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2021122309372011400_B7","doi-asserted-by":"crossref","first-page":"D652","DOI":"10.1093\/nar\/gkp995","article-title":"COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer","volume":"38","author":"Forbes","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"2021122309372011400_B8","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1093\/nar\/gkr407","article-title":"Predicting the functional impact of protein mutations: Application to cancer genomics","volume":"39","author":"Reva","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"2021122309372011400_B9","doi-asserted-by":"crossref","first-page":"D43","DOI":"10.1093\/nar\/gks1068","article-title":"Update on activities at the Universal Protein Resource (UniProt) in 2013","volume":"41","author":"UniProt Consortium","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2021122309372011400_B10","doi-asserted-by":"crossref","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: Public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2021122309372011400_B11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: The NCBI database of genetic variation","volume":"29","author":"Sherry","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"2021122309372011400_B12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","article-title":"Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets","volume":"4","author":"Balko","year":"2014","journal-title":"Cancer Discov"},{"key":"2021122309372011400_B13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.lungcan.2014.11.008","article-title":"Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma","volume":"87","author":"Schmid","year":"2015","journal-title":"Lung Cancer"},{"key":"2021122309372011400_B14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.lungcan.2014.05.009","article-title":"BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib","volume":"85","author":"Robinson","year":"2014","journal-title":"Lung Cancer"},{"key":"2021122309372011400_B15","doi-asserted-by":"crossref","first-page":"8009a","DOI":"10.1200\/jco.2013.31.15_suppl.8009","article-title":"Interim results of phase ii study brf 113928 of dabrafenib in braf v600e mutation-positive non-small cell lung cancer (nsclc) patients","volume":"31","author":"Planchard","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309372011400_B16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/jnci\/djm291","article-title":"The frequency of Muir-Torre syndrome among Lynch syndrome families","volume":"100","author":"South","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2021122309372011400_B17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/emmm.200900040","article-title":"Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2","volume":"1","author":"Martin","year":"2009","journal-title":"EMBO Mol Med"},{"key":"2021122309372011400_B18","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2014-04-531871","article-title":"Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition","volume":"124","author":"Irving","year":"2014","journal-title":"Blood"},{"key":"2021122309372011400_B19","doi-asserted-by":"crossref","first-page":"15996","DOI":"10.1073\/pnas.1019012108","article-title":"Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC\/Rheb-independent manner","volume":"108","author":"Banerjee","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309372011400_B20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122309372011400_B21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ccell.2014.08.017","article-title":"Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors","volume":"26","author":"Cheung","year":"2014","journal-title":"Cancer Cell"},{"key":"2021122309372011400_B22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-005-9044-6","article-title":"Systemic high-dose intravenous methotrexate for central nervous system metastases","volume":"78","author":"Lassman","year":"2006","journal-title":"J Neurooncol"},{"key":"2021122309372011400_B23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s002800000118","article-title":"Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis","volume":"46","author":"Tetef","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309372011400_B24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/theoncologist.2013-0405","article-title":"Molecular tumor board: The University of California-San Diego Moores Cancer Center experience","volume":"19","author":"Schwaederle","year":"2014","journal-title":"The Oncologist"},{"key":"2021122309372011400_B25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1634\/theoncologist.2014-0011","article-title":"Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel","volume":"19","author":"Johnson","year":"2014","journal-title":"The Oncologist"},{"key":"2021122309372011400_B26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.1239947","article-title":"Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma","volume":"343","author":"Johnson","year":"2014","journal-title":"Science"},{"key":"2021122309372011400_B27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1755-8794-7-2","article-title":"Whole-genome sequencing of matched primary and metastatic hepatocellular carcinomas","volume":"7","author":"Ouyang","year":"2014","journal-title":"BMC Med Genomics"},{"key":"2021122309372011400_B28","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1200\/JCO.2011.38.2994","article-title":"Comparative genomic analysis of primary versus metastatic colorectal carcinomas","volume":"30","author":"Vakiani","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309372011400_B29","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1056\/NEJMoa1403352","article-title":"Response and acquired resistance to everolimus in anaplastic thyroid cancer","volume":"371","author":"Wagle","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122309372011400_B30","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0097","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0097","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/9\/1011\/41870181\/oncolo_20_9_1011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/9\/1011\/41870181\/oncolo_20_9_1011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T03:38:18Z","timestamp":1640317098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/9\/1011\/6399682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,23]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,7,23]]},"published-print":{"date-parts":[[2015,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0097","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,9,1]]},"published":{"date-parts":[[2015,7,23]]}}}